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Summary 
Background. – Most data on the epidemiology of cardiogenic shock (CS) have come from patients 
with acute myocardial infarction admitted to intensive cardiac care units (ICCUs). However, CS can 
have other aetiologies, and could be managed in intensive care units (ICUs), especially the most 
severe forms of CS. 
Aim. – To gather data on the characteristics, management and outcomes of patients hospitalized in 
ICCUs and ICUs for CS, whatever the aetiology, in France in 2016. 
Methods. – We included all adult patients with CS between April and October 2016 in metropolitan 
France. CS was defined (at admission or during hospitalization) by: low cardiac output, defined by 
systolic blood pressure < 90 mmHg and/or the need for amines to maintain systolic blood pressure > 
90 mmHg and/or cardiac index < 2.2 L/min/m²; elevation of the left and/or right heart pressures, 
defined by clinical, radiological, biological, echocardiographic or invasive haemodynamic overload 
signs; and clinical and/or biological signs of malperfusion (lactate > 2 mmol/L, hepatic insufficiency, 
renal failure). 
Results. – Over a 6-month period, 772 patients were included in the survey (mean age 65.7 ± 14.9 
years; 71.5% men) from 49 participating centres (91.8% were public, and 77.8% of these were 
university hospitals). Ischaemic trigger was the most common cause (36.3%). 
Conclusions. – To date, FRENSHOCK is the largest CS survey; it will provide a detailed and 
comprehensive global description of the spectrum and management of patients with CS in a high-
income country. 
  
Résumé 
Contexte. – La majorité des données disponibles sur le choc cardiogénique (CC) concernent des 
patients présentant un syndrome coronarien aigu hospitalisés en soins intensifs de cardiologie. Or, les 
patients en CC peuvent avoir d’autres étiologies et être pris en charge en réanimation, avec souvent 
une défaillance multi viscérale et possiblement un profil clinique et un pronostic différent.  
But. – Faire un état des lieux des caractéristiques, de la prise en charge et du pronostic des patients 
pris en charge pour un CC quelle qu’en soit son étiologie, en France en 2016 
Méthodes. – Les patients présentant un CC entre Avril et Octobre 2016 en France ont été 
prospectivement inclus. Le CC était défini par l’association d’un critère : de bas débit cardiaque défini 
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par une pression artérielle systolique < 90 mmHg ou la nécessité d’amines vasopressives et/ou 
inotropes, et/ou par un index cardiaque < 2,2 L/min/m2 ; une élévation clinique, biologique, 
échographique ou invasive des pressions de remplissage droites et/ou gauches ; et des signes de 
malperfusion clinique et/ou biologique (lactate > 2 mmol/L, insuffisance rénale et/ou hépatique). 
Résultats. – Sur une période de 6 mois, 772 patients ont été inclus (âge moyen de 65,7 ± 14,9 ans ; 
71,5 % d’hommes) dans 49 centres (91,2 % publics dont 71,4 % universitaires). Le facteur 
déclenchant ischémique était majoritaire (36,3 %). 
Conclusions. – FRENSHOCK est à ce jour le plus vaste registre de CC toutes causes, permettant de 
faire une description précise et détaillée de la typologie et la prise en charge de ces patients dans un 
pays à haut niveau de revenu. 
 
KEYWORDS 
Cardiogenic shock;  
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 Abbreviations: AMI, acute myocardial infarction; BNP, brain natriuretic peptide; CS, cardiogenic 
shock; IABP, intra-aortic balloon pump; ICU, intensive care unit; ICCU, intensive cardiac care unit. 
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Background  
Cardiogenic shock (CS) is usually defined as a state of organ malperfusion in a context of low cardiac 
output without hypovolaemia, signalling primary cardiac failure. However, various definitions have 
been proposed [1], indicating a wide spectrum of clinical presentations and outcomes, ranging from 
mild haemodynamic perturbations considered as “pre-shock” to much more severe haemodynamic 
compromise leading to multiorgan failure [2].  
 Despite renewed interest and effort in recent years, with some large-scale randomized studies [3-
5] in CS complicating acute myocardial infarction (AMI-CS), data on CS are scarce compared with 
other shock aetiologies. Most recommendations for CS management are low level in European 
guidelines [6]. Few strong recommendations exist, based on evidence from randomized studies, and 
which advocate urgent revascularization [3] and discourage the systematic use of an intra-aortic 
balloon pump (IABP) for AMI-CS [4, 5]. These contrast with weak recommendations regarding the use 
of catecholamines in the management of CS, in the absence of large dedicated randomized studies 
[7-9]. Consequently, there is a need for good quality and large-scale observational data [10]. Most 
data have been provided by health insurance (National Institutes of Health) database analyses in the 
USA [11-13] and acute coronary syndrome registries in the USA [14-16] and Europe [17-20]; these 
registries focused mainly on AMI-CS. Fewer data are available on all-cause CS, and results are 
discordant. The main registry is the recent prospective multicentre CARDSHOCK registry, which 
included 219 patients in nine European centres and reported a clear preponderance of AMI-CS (80%) 
[21]. In contrast, recent analyses of databases from France and the USA have suggested a clear 
increase in non-ischaemic aetiologies (up to 60% of CS cases). Furthermore, this study showed an 
increase in the prevalence of CS in intensive care (from 4.1% to 7.7% between 1997 and 2012) [22], 
and persistence of a high mortality rate, advocating further specific research [13, 16, 22]. Moreover, 
little is known about networks dedicated to CS, despite the fact that they could play a major role in the 
management of these patients [23]. 
 The FRENSHOCK registry was a multicentre national registry that aimed to capture all instances 
of CS during a specific time window. The registry was designed to describe population characteristics, 
aetiologies, pathways, management and outcomes in everyday practice. The main objectives were to 
provide a precise overview of all-cause CS in France in 2016, and to assess 30-day and 1-year 
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outcomes of patients with CS. In this report, we present the design of the FRENSHOCK registry, and 
compared it with previous CS registries. 
 
Methods 
Study design 
FRENSHOCK was a prospective multicentre observational survey conducted in metropolitan France 
during a 6-month period between April and October 2016 (Clinicaltrials.gov Identifier: NCT02703038). 
The general organization of the FRENSHOCK registry is presented in Appendix A.  
 
Population 
The study inclusion criteria are described in Table 1. Patients aged > 18 years were included 
prospectively, regardless of the CS aetiology, if they met at least one criterion in each of the following 
three components: (1) low cardiac output, defined by systolic blood pressure < 90 mmHg and/or the 
need for amines to maintain systolic blood pressure > 90 mmHg and/or cardiac index < 2.2 L/min/m² 
on echocardiography or right heart catheterization; (2) elevation of left and/or right heart pressures, 
defined by clinical signs, radiology (overload signs on chest X-ray or computed tomography scan), 
biological tests (natriuretic peptide elevation), echocardiography (usual signs of left ventricular filling 
pressure elevation) or invasive haemodynamic overload signs (elevation of mean pulmonary artery 
pressure or pulmonary capillary wedge pressure); and (3) signs of malperfusion, which could be 
clinical (oliguria, mottling, confusion) and/or biological (lactate > 2 mmol/L, hepatic insufficiency, renal 
failure). 
 Patients admitted after resuscitation of a cardiac arrest were included if they fulfilled previously 
defined CS criteria. Patients could be included regardless of whether CS was initial or secondary. 
 Exclusion criteria were refusal or inability to consent and diagnosis of CS refuted in favour of 
alternative diagnoses, such as septic shock, refractory cardiac arrest and postcardiotomy CS. 
 
Organization and funding 
Participating centres 
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At the end of 2015, participation in the study was offered to all types of institutions (academic 
hospitals, general hospitals and private clinics), and to all types of units that manage patients with CS 
in France (intensive cardiac care units [ICCUs], surgical intensive care units [ICUs], medical ICUs and 
general ICUs).  
 
Data collected 
Patient demographic data and information about socioprofessional situation (active, retired, disabled 
or unemployed) were recorded. Cardiovascular history, coexisting medical conditions (chronic kidney 
disease, pulmonary or neurological disease, cancer, etc.), risk factors (smoking status, hypertension, 
dyslipidaemia and diabetes mellitus), treatment at admission and clinical presentation were recorded.  
 Up to three CS triggers among the following were considered for each patient: ischaemic (type 1 
or type 2 AMI according to European guidelines), mechanical complications, ventricular and 
supraventricular arrhythmia, severe bradycardia, iatrogenic events, infections and/or non-observance 
of previous medication. Investigators could also note if other factors or aetiologies existed – these 
triggering factors were marked as "others". 
 The care path and the time of care were specified: type of first medical contact, initial place of 
care, possible transfer to a tertiary centre and the corresponding deadlines. 
 Clinical, biological and echocardiographical data during the first 24 hours after admission were 
collected. Clinical data included blood pressure, heart rate, presence of signs of left and right heart 
failure (including Killip class), presence of mottling and presence of sinus rhythm. Biological data 
included serum electrolytes, renal and hepatic function and haemostasis, arterial and venous (ScVO2) 
blood gases and arterial lactate, C-reactive protein, troponin and B-type natriuretic peptide (BNP) or 
N-terminal prohormone of BNP concentrations. Each concentration was measured in each 
investigating centre with its own dosage and reference value. Echocardiograms were done by the 
doctor in charge of the patient (cardiologist or intensivist), regardless of their level of expertise [24]. 
Mandatory echocardiographic data included left ventricular ejection fraction (visual evaluation or 
Simpson’s biplane), presence of pericardial effusion and presence of severe valvulopathy (defined as 
grade IV). Additional echocardiographic variables were favoured, but not mandatory (right ventricular 
function and overload variables based on the usual expert recommendations) [25].  
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 The in-hospital CS management data recorded included use of inotropes and vasopressors (type, 
dose and duration), diuretics (type and dose), organ replacement therapies as ventilation (mechanical 
or non-invasive, and duration), temporary mechanical circulatory support (type of IABP; extracorporeal 
membrane oxygenation or Impella® (Abiomed, Danvers, MA, USA); and duration) and renal 
replacement therapy (continuous or intermittent type, indication and duration). End-stage heart failure 
treatment was recorded as urgent heart transplant list registration, bridge to a left ventricular assist 
device, total artificial heart or heart transplantation. If carried out, data from right heart catheterization, 
coronary angiography, revascularization by coronary artery bypass graft and/or percutaneous 
coronary intervention, but also any surgery, were collected. Information on in-hospital complications, 
such as stroke, bleedings and transfusions, haemolysis, thrombocytopoenia, infection, vascular 
complications and death, were collected.  
 
Follow-up 
Several follow-up points were considered, and are described in Table 2: at hospital discharge and 30 
days by the local investigator; and at 1 year by dedicated research technicians based at the French 
Society of Cardiology.  
 At 1 year, follow-up was performed using the following sequential procedure: first, consult the 
registry office of the patient’s birthplace for death certificates; then, contact the patient’s general 
practitioner and/or cardiologist; and finally, contact the patient or their direct relatives. In many 
instances, written contact was followed by a telephone interview with the patient or their family to 
clarify mode of living, presence of left ventricular or biventricular assist device or heart transplantation, 
ongoing treatment and eventual return to work 
 
Data quality 
Data quality was ensured using numerous automated checks when the electronic case record forms 
were completed, and by the fact that some data entered were verified, and modified if necessary, by 
external research assistants from the French Society of Cardiology after verification with the patient's 
referring investigators. Completeness of the data was adequate for most variables (e.g. rates of 
missing values were 3.5% for height, 2.2% for weight, < 0.5% for admission blood pressure and heart 
rate and < 0.3% for previous cardiomyopathy). Once entered into the electronic case record form, data 
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were stored in a central database at the French Society of Cardiology in Paris. Data management is 
ensured, in conjunction with the French Society of Cardiology and Toulouse University. 
 
Legal issues 
Written informed consent was provided by each patient. Patients who died early after admission were 
not screened, and were not included as informed consent could not be obtained. The study was 
conducted in compliance with Good Clinical Practice, French law and the French data protection law. 
The data that were recorded and their handling and storage were reviewed and approved by the 
Comité consultatif sur le traitement de l’information en matière de recherche dans le domaine de la 
santé (CCTIRS) (n° 15.897) and the Commission Nationale Informatique et Liberté (CNIL) (n° DR-
2016-109). The study is registered with ClinicalTrials.gov (Identifier: NCT02703038). 
 
Funding and data property 
This was a French Society of Cardiology registry, carried out by its Emergency and Intensive Cardiac 
Care Unit group. The study was sponsored by the Fédération Française de Cardiologie, and was 
funded by unrestricted grants from Daiichi-Sankyo and Maquet SAS. Complementary grants will be 
sought for dedicated research projects within the main study. 
 
Statistical analysis 
Quantitative data are reported using means ± standard deviations, or medians (interquartile ranges) 
when skewed. Qualitative data are presented as numbers and percentages.  
 Planned analyses will compare different groups of patients with CS: patients with ischaemic and 
non-ischaemic CS or with and without clinical hypotension or with and without right failure. Univariate 
analyses for comparisons between groups will be performed using classical statistical tests: the χ² test 
or Fisher’s exact test for categorical data, and Student’s t test or analysis of variance for quantitative 
data. Non-parametric tests will be used when needed. Multivariable analyses will be conducted using 
appropriate methods (multiple logistic regression). 
 Global mortality after 30 days and after 1 year will be studied using Kaplan−Meier survival 
analyses. Relationships between patient characteristics and 30-day or 1-year mortality will be tested 
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using log-rank tests, and multivariable analyses will be performed using a Cox proportional hazards 
regression model. 
 All analyses will be performed using Stata statistical software, version 10 (StataCorp, College 
Station, TX, USA) 
 
Results 
Population description 
A total of 777 patients were included initially, but five were excluded because they had been enrolled 
twice; 772 patients were therefore included in the final analysis. 
 Among the 52 centres that agreed to participate, 49 were active (Fig. 1): 35 academic hospitals, 
10 general hospitals and four private clinics. Inclusion per centre varied from 1 to 72 patients, 
predominantly in public hospitals (n = 731; 94.7%), and particularly university hospitals (n = 670; 
86.8%) (Appendix B). 
 The first preliminary results from the FRENSHOCK registry are presented in Table 3. Patients 
were mostly men (71.5%), with a mean age of 65.7 ± 14.9 years. More than half had previous 
cardiomyopathy, especially of ischaemic origin. Patients had comorbidities – frequently previous 
myocardial revascularization, peripheral vascular disease, stroke, chronic obstructive pulmonary 
disease and chronic organ failure. More than one-third of the population had no cardiovascular risk 
factors. The CS aetiology often had several triggers, but ischaemic was most common (36.3%), 
although type 1 AMI concerned only 17.2% of the population. Patients were managed and included in 
ICCUs (70.2%) or ICUs (general, medical or surgical) (29.8%). 
 
Discussion  
To our knowledge, FRENSHOCK is the largest published multicentre prospective study on CS of all 
aetiologies to date, with 772 patients included in 49 centres. FRENSHOCK will offer unique insights 
into real-life practice, though the participation of university and non-university hospitals as well as 
public and private centres. 
 This study derives its originality from the inclusion of patients who would usually have been 
excluded from previous studies because of restrictive inclusion/exclusion criteria. Patients could be 
included if they were aged > 18 years, because of administrative regulations, but without an upper age 
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restriction; patients aged up to 98 years could therefore be included for the first time. In ageing 
societies, elderly people represent a growing proportion of hospitalizations in ICUs and ICCUs (42.1% 
aged > 75 years and 15.5% aged > 85 years in ICCUs in 2014 in France [26]), but have largely been 
underconsidered in other studies; here, our methods enabled us to describe CS in elderly patients, in 
terms of characteristics, care and prognosis. Furthermore, our innovative inclusion criteria took into 
account the limitations of CS definitions, which is a strength of the study. 
 Our CS definition is pragmatic and practical, based on simple criteria available at the patient's 
bedside in any centre, regardless of its level of expertise, allowing rapid recognition and inclusion of 
patients in primary, secondary and tertiary care centres. Our definition is easy to use, to remember 
and to apply in daily practice. Indeed, to be considered as having CS, patients had to fulfil only three 
criteria: one low flow criterion, one overload criterion and one organ malperfusion criterion.  
 Contrary to previous definitions [1], typical daily non-invasive paraclinical approaches could be 
used to define low cardiac output (echocardiography) and overload variables (natriuretic peptides 
elevation, echocardiography, computed tomography and/or chest X-ray). Invasive haemodynamic 
evaluation by right heart catheterization was possible, but not mandatory, unlike in some previous 
trials (including the SHOCK study [3]).  
 To date, classical CS definitions have been based on and created for AMI-CS; in the SHOCK and 
IABP SHOCK II study definitions [3, 5], patients had to present signs of left heart failure, defined by 
clinical signs (pulmonary congestion) and/or haemodynamic signs (pulmonary capillary wedge 
pressure elevation > 15 mmHg), restricting the CS definition to ischaemic CS (predominantly left). 
Here, inclusions were not restricted to ischaemic CS or AMI-CS in centres capable of percutaneous 
coronary intervention, enabling us to address the lack of data in non-ischaemic CS. Thus, the 
inclusion of a majority of patients without an ischaemic trigger should provide interesting data in this 
population.  
 In addition, the FRENSHOCK definition of CS allows us to include patients with isolated or 
predominantly right heart failure, as right heart failure signs are part of the definition of the overload 
component of the registry. Importantly, these patients were discarded in previous studies and 
registries dedicated to patients with AMI-CS, despite a high prevalence (30–45%) [27] and a poor 
prognosis for right heart failure in patients with CS [28].  
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 Further, patients with low cardiac output, congestion and malperfusion, but without “strictly” 
hypotension, were also taken into account, which is original and may provide useful data in this 
population, as their prognosis seems similar to that for patients with classical definitions of shock [29].  
 Altogether, this large study paints an accurate picture of contemporary clinical practice, and 
hence provides a better description of understudied populations. 
 To date, data on CS diagnosis, epidemiology, outcomes and management are scarce compared 
with other types of shock. For example, there were 32,749 references in PubMed and 519 ClinicalTrial 
identifiers for septic shock in September 2018 compared with 13,144 and 66, respectively, for CS. 
Furthermore, only 29 were prospective observational or interventional studies, and only nine had more 
than two investigating centres (Table 4). Through the FRENSHOCK database, we have many 
opportunities to acquire knowledge about CS. Thus, subgroup analyses are planned, including 
dichotomic variables, such as right failure non-ischaemic CS, and continuous variables, such as age. 
The aim is to better understand the pathophysiological and prognostic differences in these previously 
poorly described populations. Various therapeutic strategies are used, and their link with outcomes will 
be detailed and analysed. 
 
Study limitations 
First, inclusions were not exhaustive, and probably were not consecutive in all centres, because some 
centres with a known high volume of patients with CS included fewer than five patients during the 6-
month inclusion period. Moreover, non-inclusions and reasons for not including patients were not 
counted. Therefore, we can approach the wide spectrum of CS in real-life practice in France, but not 
its incidence, even if FRENSHOCK is the largest survey to date on patients with CS, facilitating future 
appealing analyses.  
 Second, almost three-quarters of the inclusions were in academic centres, which prevents 
extrapolation of the results to all centres. However, in practice in France, we can expect that patients 
with CS are transferred to expert centres with a technical platform to support them, which limits this 
selective bias.  
 Third, this was an observational survey, with its intrinsic biases, and some data should be 
interpreted with caution. As a real-life survey, no previous level of expertise was required to perform or 
interpret imaging. Echocardiograms were performed in each centre by the physician in charge of the 
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patient, who could be a cardiologist or an intensivist, depending on the type of structure and place 
(emergency room, ICCU or ICU). The absence of imaging standardization and centralization (core 
laboratory) could be a source of bias in the definition of CS and its type. However, as quoted in an 
expert consensus statement, echocardiographic markers of CS, defined as the basic competence in 
critical care echocardiography, should be easily recognized by operators with minimal training [24]. 
Moreover as a non-interventional survey, the impact of different medications and management 
strategies should be assessed with caution [30].  
 Finally, data from patients who died early (i.e. before informed consent was obtained) were not 
collected and recorded in the database because of administrative regulations; this could be a source 
of bias, leading to an underestimation of mortality in our cohort. 
 
Conclusions 
As a result of its broad inclusion criteria and limited exclusion criteria, the FRENSHOCK survey will 
provide a large and original dataset on contemporary CS; it will facilitate important subgroup analysis 
of aetiologies excluded from previous registries and trials. This is the largest prospective multicentre 
survey of CS of all causes, allowing a contemporary description of CS in everyday clinical practice in 
France.  
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Figure legend 
 
Figure 1. Geographic distribution of the centres participating in the FRENSHOCK registry. 
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Table 1 Inclusion criteria (FRENSHOCK definition of cardiogenic shock). 
Component Criteria 
Low cardiac output SBP < 90 mmHg or need for vasopressors/inotropes to maintain SBP > 90 mmHg 
 CI < 2.2 L/min/m2 (by echocardiography and/or invasive haemodynamic evaluation with right heart catheterization) 
Right and/or left overload Clinical assessments (dyspnoea, rales and crepitations, jugular venous distension and/or abdominojugular test, oedema) 
 Biological tests (NT-proBNP > 900 pg/mL and/or BNP > 400 pg/mL) 
 Radiology (overload signs on chest X-ray and/or chest tomodensitometry) 
 Echocardiography (E/A > 2 if LVEF < 45% or E/Ea > 13 if LVEF normal; or sPAP > 35 mmHg and/or E deceleration time < 150 
ms and/or Ap-Am > 30 ms and/or E/Vp ≥ 2.5) 
 Invasive haemodynamic evaluation with right heart catheterization (PCWP > 15 mmHg and/or mPAP > 25 mmHg) 
Organ malperfusion Clinical (oliguria < 0.5mL/kg/h, confusion, cold/clammy skin and extremities and/or marbling) 
 Biology (lactate > 2 mmol/L, metabolic acidosis, liver insufficiency and/or renal failure) 
To be considered to have cardiogenic shock, patients had to fulfil at least one criterion from each of the three components: low cardiac output; left and/or right 
overload; and organ malperfusion. BNP: B-type natriuretic peptide; CI: cardiac index; LVEF: left ventricular ejection fraction; mPAP: mean pulmonary arterial 
pressure; NT-proBNP: N-terminal prohormone of B-type natriuretic peptide; PCWP: pulmonary capillary wedge pressure; SBP: systolic blood pressure. 
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Table 2 Planned follow-up in the FRENSHOCK registry 
  Hospital discharge 30 days 1 year 
NYHA class X   X 
LVEF X     
Ongoing medications X   X 
Mode of living X   X 
Return to work X   X 
Vital status X X X 
Terminal heart failure treatment X X X 
 LVAD X X X 
 BiVAD or TAH X X X 
 HTx X X X 
BiVAD: biventricular assist device; HTx: heart transplantation; LVAD: left ventricular assist device; 
LVEF: left ventricular ejection fraction; NYHA: New York Heart Association classification of 
dyspnoea; TAH: total artificial heart. 
 
 
 
19 
 
 
Table 3 Main characteristics of the FRENSHOCK population (n = 772). 
Age (years) 65.7 ± 14.9 
Men 552 (71.5) 
BMI (kg/m2) 25.8 ± 5.5 
Cardiovascular risk factors   
 Diabetes 217 (28.2) 
 Hypertension 343 (44.5) 
 Dyslipidaemia 241 (31.3) 
 Current smoker 206 (27.8) 
Main medical history   
 Peripheral artery disease 114 (14.8) 
 Previous myocardial revascularization 203 (26.3) 
 Chronic renal failure 164 (21.3) 
 Chronic dialysis 11 (1.4) 
 COPD 50 (6.5) 
 Chronic respiratory failure 8 (1.0) 
 Active neoplasia 51 (6.6) 
  Stroke 62 (8.0) 
Previous known cardiopathy   
 Ischaemic 230 (29.8) 
 Hypertrophic 11 (1.4) 
 Posthypertensive 24 (3.1) 
 Valvular 65 (8.4) 
 Dilated  110 (14.3) 
 Others 76 (9.9) 
Previous MSP and/or IAD 162 (21.0) 
Ischaemic trigger CS 280 (36.3) 
 Type 1 MI 133 (67.5) 
Cardiac arrest before admission 79 (10.3) 
20 
 
Support unit   
 ICCU 414/590 (70.2) 
 ICU 176/590 (29.8) 
Data are expressed as mean ± standard deviation or number (%). BMI: body mass index; 
COPD: chronic obstructive pulmonary disease; CS: cardiogenic shock; IAD: internal automatic 
defibrillator; ICCU: intensive cardiac care unit; ICU: intensive care unit; MI: myocardial 
infarction; MSP: multisite pacing. 
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Table 4 Ongoing or scheduled prospective trials on cardiogenic shock.  
Country Clinical trial 
identifier 
Title Intervention Primary endpoints Start date 
(M/Y) 
Centres 
(n) 
Patients 
included (n) 
CS 
aetiologies 
Estimated 
completion 
date (M/Y) 
France NCT03528291 Transient Circulatory Support 
in CS (ALLOASSIST) 
Observational In-hospital mortality 05/2018 ? 240 Miscellaneous 01/2018 
Indonesia NCT03635840 The Effects of IABP Prior to 
Revascularization on Mortality 
of ACS Patients Complicated 
With CS 
RT; parallel 
assignment 
30-day mortality 01/2018 1 92 ACS 12/2018 
USA NCT03141255 CS Intravascular Cooling Trial 
(CHILL-SHOCK) 
RCT; pilot 
study 
Safety (arrythmia, 
bleedings, 
hypokalaemia, 
bloodstream infection) 
11/2017 1 20 Miscellaneous /062019 
USA NCT03378739 Implementation of a CS Team 
and Clinical Outcomes (INOVA 
SHOCK Registry) 
Observational 1-year mortality 01/2018 1 400 Miscellaneous 11/2018 
France NCT03340779 Norepinephrine vs 
Norepinephrine and 
Interventional; 
crossover 
Haemodynamic 
variables 
01/2018 1 40 Miscellaneous 11/2019 
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Dobutamine in CS (SHOCK-
NORDOB) 
assignment 
France NCT03283995 Haemodynamic Assessment 
in CS Regarding the Etiology 
Observational Transpulmonary 
thermodilution at 48 
hours 
09/2017 1 64 Miscellaneous 09/2019 
USA NCT03431467 Impella CP With VA ECMO 
for CS (REVERSE) 
RT; parallel 
assignment 
Survival free from HTx, 
LVAD or inotropes at 
30 days 
03/2018 1 96 Miscellaneous 01/2021 
Spain NCT03437369 Efficacy and Safety on Heart 
Rate Control With Ivabradine 
on CS (ES-FISH) 
RCT; pilot 
study 
Change in cardiac 
output and heart rate at 
24 hours 
05/2018 1 22 Miscellaneous 10/2019 
Italy NCT02591771 Study of Multistep 
Pharmacological and Invasive 
Management for CS 
Phase 2 trial 
with single 
group 
60-day survival 10/2015 2 24 Miscellaneous 11/2018 
Czech Republic NCT02301819 ECMO in the Therapy 
of CS (ECMO-CS) 
RT; parallel 
assignment 
Death from any cause, 
resuscitated circulatory 
arrest and implantation 
of another MCSD at 30 
days 
09/2014 3 120 Miscellaneous 06/2019 
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Germany NCT02544594 Clinical Study of Extra-Corporal 
Life Support in CS Complicating 
AMI (ECLS-SHOCK) 
RT; parallel 
assignment 
LVEF at 30 days 11/2015 1 42 ACS 03/2019 
China NCT02870946 The Effect of Simultaneous 
Renal Replacement Therapy on 
ECMO Support for CS Patients 
RT; parallel 
assignment 
30-day mortality 08/2016 1 262 Miscellaneous 12/2018 
Denmark/Germany NCT01633502 Danish CS Trial RT; parallel 
assignment 
6-month mortality 12/2012 7 360  ACS/only 
STEMI 
09/2022 
USA NCT02790242 Registry for CS: Utility and 
Efficacy of Device Therapy 
(RESCUE) 
Observational 1-year survival after 
MCSD implantation 
11/2013 7 200,000 Miscellaneous 08/2018 
Germany/UE NCT03637205 Extracorporeal Life Support 
in CS (ECLS-SHOCK) 
RT; parallel 
assignment 
30-day mortality 10/2018 ? 420  ACS 01/2022 
USA NCT03387605 Effect of Ivabradine in Stage D 
HF/CS Patients on Dobutamine 
RCT Heart rate during first 
72 hours 
03/2018 1 40 Miscellaneous 01/2020 
Czech Republic NCT03551964 Dual Antiplatelet Therapy 
For Shock Patients With AMI 
(DAPT-SHOCK-AMI) 
RCT Death/MI/stroke at 30 
days 
08/2018 12 304 ACS 06/2020 
China NCT03549923 Evaluation of Early CRRT and RCT 30-day mortality 06/2018 ? 550 Miscellaneous 06/2022 
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Beta-blocker Interventions in 
Patients With ECMO (ELITE) 
UK NCT03532529 Evaluation of Speckle Tracking 
Parameters as Predictors of 
Successful VA ECMO Weaning 
Procedure.  
Observational; 
pilot study 
Death from any cause, 
HTx or new 
implantation of another 
MCSD at 30 days 
09/2018 1 24 Miscellaneous 11/2019 
France NCT03327493 Impact of Adrenoreceptor 
Expressions on Inflammatory 
Pattern in Refractory CS Under 
VA ECMO (ADRECMO) 
Interventional; 
single-arm 
assignment 
Change in cytokine 
during ECMO support 
10/2017 1 40 Miscellaneous 09/2019 
France NCT03436641 Microcirculation in CS 
(MicroShock) 
Observational Incidence of 
microcirculatory 
impairment in CS and 
28-day mortality 
05/2018 2 100 Miscellaneous 03/2020 
Germany NCT02697006 Synchronized Cardiac Assist for 
CS. The SynCor trial. 
Observational Safety and efficacy of i-
cor device implantation 
01/2016 1 48 ACS 05/2018 
Korea NCT02985008 Clinical Outcomes and Efficacy 
of LVAD for Korean Patients 
With CS: RESCUE 
Observational In-hospital mortality 04/2016 ? 1000 Miscellaneous 12/2019 
25 
 
Canada NCT03207165 Milrinone Versus Dobutamine in 
Critically Ill Patients 
RT; parallel 
assignment 
In-hospital mortality 08/2017 1 192 ACS 06/2020 
France NCT02754193 Effects of Induced Moderate 
HYPOthermia on Mortality 
in CS Patients Rescued by VA 
ECMO (HYPO-ECMO) 
RT; parallel 
assignment 
30-day mortality 07/2016 19 334 Miscellaneous 09/2019 
Sixty-six studies were found to be registered on “clinicaltrials.gov” in September 2018 using the keyword “cardiogenic shock”; we deleted terminated or completed studies (n= 26), 
studies not exclusively concerning patients with CS (n = 7), studies that had been withdrawn or with status unknown (n = 4) and studies with a retrospective design (n = 4). Only 
trials including patients exclusively with CS are presented (e.g. patients benefiting from percutaneous coronary intervention at high risk are not presented). AMI: acute myocardial 
infarction; ACS: acute coronary syndrome; CRRT: continuous renal replacement therapy; CS: cardiogenic shock; ECMO: extracorporeal membrane oxygenation; HF: heart failure; 
HTx: heart transplantation; IABP: intra-aortic balloon pump; LVAD: left ventricular assist device; LVEF: left ventricular ejection fraction; M: month; MCSD: mechanical circulatory 
support device; MI: myocardial infarction; RCT: randomized controlled trial; RT: randomized trial; STEMI: ST-segment elevation myocardial infarction; VA: venoarterial; Y: year.  
 
26 
 
